154229-20-6

Basic information

• Product Name: Anhydro Abiraterone
• Synonyms: Anhydro Abiraterone;Abiraterone Acetate IMP
• CAS NO: 154229-20-6
• Molecular Formula: C24H29N
• Molecular Weight: 331.49376
• Mol File: 154229-20-6.mol

Chemical Properties

• Boiling Point: 475.0±45.0 °C(Predicted)
• Appearance: /
• Density: 1.10±0.1 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 5.31±0.12(Predicted)
• CAS DataBase Reference: Anhydro Abiraterone(CAS DataBase Reference)
• NIST Chemistry Reference: Anhydro Abiraterone(154229-20-6)
• EPA Substance Registry System: Anhydro Abiraterone(154229-20-6)

Safety Data

• Hazardous Substances Data: 154229-20-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Anhydro Abiraterone is used as a potential drug for the treatment of androgen-dependent prostate cancer. It functions by inhibiting the enzyme CYP17, which is essential for androgen synthesis, thereby disrupting the growth and progression of prostate cancer cells.
Anhydro Abiraterone is used as a research compound for the development of novel therapeutic strategies against androgen-dependent prostate cancer. Its role in inhibiting the enzyme CYP17 makes it a valuable candidate for further investigation and potential clinical application in the treatment of this specific type of cancer.

Upstream product

• 497-19-8 sodium carbonate 
• 89878-14-8 3-Diethylboranylpyridine 
• 154229-36-4 androsta-3,5,16-trien-17-yl trifluoromethanesulfonate 
• 853-23-6 prasterone acetate 

Relevant articles and documents

17-substituted steroids useful in cancer treatment

Compounds of the general formula (1) STR1 wherein X represents the residue of the A, B and C rings of a steroid, R represents a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, R 14 represents a hydrogen atom and R 15 represents a hydrogen atom or an alkyl or alkoxy group of 1-4 carbon atoms, or a hydroxy or alkylcarbonyloxy group of 2 to 5 carbon atoms or R 14 and R 15 together represent a double bond, and R 16 represents a hydrogen atom or an alkyl group of 1 to 4 carbon atoms, in the form of the free bases or phannaceutically acceptable acid addition salts, are useful for treatment of androgen-dependent disorders, especially prostatic cancer, and also oestrogen-dependent disorders such as breast cancer.

Novel Steroidal Inhibitors of Human Cytochrome P45017α (17α-Hydroxylase-C17,20-lyase): Potential Agents for the Treatment of Prostatic Cancer

Steroidal compounds having a 17-(3-pyridyl) substituent together with a 16,17-double bond have been synthesized, using a palladium-catalyzed cross-coupling reaction of a 17-enol triflate with diethyl(3-pyridyl)borane, which are potent inhibitors of human testicular 17α-hydroxylase-C17,20-lyase.The requirement for these structural features is stringent: compounds having 2-pyridyl (9), 4-pyridyl (10), or 2-pyridylmethyl (11) substituents instead of the 3-pyridyl substituent were either poor inhibitors or noninhibitory.Reduction of the 16,17-double bond to give 17β-pyridyl derivatives diminished potency with 3-pyridyl substitution (327; IC50 for lyase, 2.923 nM) but increased it with a 4-pyridyl substituent present (1028; IC50 1 μM53 nM).In contrast, a variety of substitution patterns in rings A-C of the steroid skeleton afforded inhibitors having potencies similar to those most closely related structurally to the natural substrates pregnenolone and progesterone, respectively 17-(3-pyridyl)androsta-5,16-dien-3β-ol (3, Kiapp 1 nM; IC50 for lyase, 2.9 nM) and 17-(3-pyridyl)androsta-4,16-dien-3-one (15; IC50 for lyase, 2.1 nM).Thus compounds having variously aromatic ring A (18), saturated rings A/B (21,22), and oxygenated ring C (26) exhibited IC50 values for lyase (1.8-3.0 nM) falling within a 2-fold range.The most potent compounds are candidates for development as drugs for the treatment of hormone-dependent prostatic carcinoma.